NIKKEI 225
38,837.46 -85.54 (-0.22%) HANG SENG
18,444.11 +41.11 (+0.22%) CRUDE OIL
72.92 -1.30 (-1.75%) GOLD FUTURES
2,346.40 -22.90 (-0.97%) DOW
38,711.29 +140.26 (+0.36%) Bitcoin GBP
55,140.27 +1,021.82 (+1.89%)
GILD Jan 2025 60.000 call
- Benzinga
National Institutes of Health Kickstarts Gilead Sponsored Trials For Twice-Yearly HIV Prevention Injection
U.S. National Institutes of Health has launched two clinical trials to examine a novel long-acting form of HIV pre-exposure prophylaxis (PrEP) in cisgender women and people who inject drugs. The mid-stage studies will assess the safety, acceptability, and pharmacokinetics (how a drug moves through the body) of lenacapavir, an antiretroviral drug administered by injection every six months. Gilead Sciences Inc. (NASDAQ:GILD) sponsored and funded the studies implemented through the HIV Prevention T
- Zacks
The Zacks Analyst Blog Highlights NextEra Energy, BP, Gilead Sciences, Hamilton Beach and FONAR
NextEra Energy, BP, Gilead Sciences, Hamilton Beach and FONAR are part of the Zacks top Analyst Blog.
- Insider Monkey
Hedge Funds are Bullish on This Gene Therapy Stock
We recently compiled a list of the 9 Best Gene Therapy Stocks to Buy Now and in this article, we discuss Gilead Sciences, Inc. (NASDAQ:GILD), which is one of the best gene therapy stocks to buy now. Gene therapy involves treating illnesses by modifying, replacing, or supplementing faulty or missing genes responsible for a disease. […]
